JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

Cancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.

Proteome Science is an esteemed academic journal specializing in the field of proteomics, providing a platform for advanced research and discussions surrounding the structure, function, and dynamics of proteins in biological systems. Published by BMC, a reputable publisher recognized for its commitment to open-access publishing, Proteome Science has been disseminating pivotal research findings since its inception in 2003. Targeted towards researchers, professionals, and students in biochemistry and molecular biology, the journal aims to foster collaboration and innovation within the scientific community. While it currently holds a Q3 quartile ranking in both Biochemistry and Molecular Biology categories, its impactful contributions to the field are reflected in its accessibility, as evidenced by its open access policy. By embracing collaborative research methodologies and providing a platform for novel findings, Proteome Science plays a crucial role in advancing the understanding of proteomic analyses, catering to a global audience that values groundbreaking scientific discovery.

Cancer Informatics, published by SAGE PUBLICATIONS LTD, is a leading open-access journal dedicated to the integration of computational techniques and cancer research. Since its inception in 2005, this journal has become a vital resource for researchers, professionals, and students interested in the intersection of informatics and oncology. With an E-ISSN of 1176-9351 and a focus on the innovative application of data analysis in cancer research, Cancer Informatics serves to disseminate critical findings that aid in understanding cancer biology and enhancing treatment modalities. Recognized in the Q3 category for both Cancer Research and Oncology according to the 2023 metrics, it currently holds a Scopus ranking of #246 in Medicine _ Oncology and #172 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, indicating its contribution to ongoing research in these fields. This journal not only supports open access to scientific findings but also aims to foster collaboration among interdisciplinary scholars worldwide, making it an essential platform for advancing the field of cancer informatics through cutting-edge research and innovative methodologies.

BMC Bioinformatics is a leading open-access journal published by BMC, dedicated to the rapidly evolving field of bioinformatics. With its inception in 2000, the journal has established itself as an essential resource for researchers, professionals, and students alike, disseminating high-quality research that bridges the gap between biology and computational science. BMC Bioinformatics holds a reputable Q1 ranking in Applied Mathematics and Computer Science Applications, and a Q2 ranking in both Biochemistry and Structural Biology, reflecting its significant impact in these interdisciplinary fields. The journal's broad scope encompasses innovative methodologies, tools, and applications that drive progress in biological research through computational approaches. With open access since its inception, the journal ensures unrestricted availability of cutting-edge research findings, promoting knowledge sharing and collaboration in the global scientific community. As it continues to publish advancements up to 2024, BMC Bioinformatics remains a cornerstone for those seeking to enhance their understanding of bioinformatics and its vital role in modern science.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.